A pharmaceutical firm’s fair trade complaint targeting purified eicosapentaenoic acid (EPA) dietary supplements or omega-3 formulations containing primarily EPA in ethyl ester or re-esterified raises a broader issue of concern to supplement marketers: FDA's criteria for allowing the use of certain ingredients in supplement products.
Amarin Corp. PLC’s complaint filed on Aug. 30 with the US International Trade Commission more narrowly could affect the...






